Clincosm LogoSign in Get a demo

A Retrospective Analysis: Whether Five Factors Affect PFS in Patients With Locally Advanced Cervical Cancer

Sponsor
Chongqing University Cancer Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05779111
Collaborator
(none)
183
Enrollment
1
Location
10
Actual Duration (Months)
18.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In previous studies, the investigators found that five factors were effective in predicting the probability of locally advanced cervical cancer with para-aortic lymph node metastasis.A retrospective study was conducted to explore the influence of 5 factors on PFS in patients with locally advanced cervical cancer receiving radiotherapy and chemotherapy.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    In previous studies, the investigators found that five factors were effective in predicting the probability of locally advanced cervical cancer with para-aortic lymph node metastasis.5 factors included positive iliac lymph nodes, histological type, tumor size, positive pelvic lymph nodes on both sides, and maximum lymph node diameter greater than 1cm. Different factors give different scores.If the score is higher than 3, the probability of retroperitoneal lymph node metastasis in patients with locally advanced cervical cancer is significantly increased, and the prognosis of patients is affected. Patients with locally advanced cervix receiving radical radiotherapy were scored based on 5 factors.Patients with scores greater than or equal to 3 points were compared with patients with scores less than 3 points.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    183 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    A Retrospective Analysis: Whether Five Factors Affect PFS in Patients With Locally Advanced Cervical Cancer
    Actual Study Start Date :
    Feb 10, 2022
    Actual Primary Completion Date :
    Nov 1, 2022
    Actual Study Completion Date :
    Dec 10, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Scores greater than or equal to 3 in patients with locally advanced cervical cancer

    Scores greater than or equal to 3 in patients with locally advanced cervical cancer
    Patients with locally advanced cervical cancer scored less than 3 points

    Patients receiving radiotherapy for locally advanced cervical cancer were scored according to five factors, with a score of less than 3

    Outcome Measures

    Primary Outcome Measures

    1. Progression Free Survival（PFS） [3 months]

      Whether there are differences in PFS between the two groups

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No

    Locally advanced cervical cancer patients receiving radiotherapy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Chongqing Cancer Hospital Chongqing Chongqing China 400030

    Sponsors and Collaborators

    • Chongqing University Cancer Hospital

    Investigators

    • Study Director: Zou Dongling, M.D., Chongqing University Cancer Hospital Chongqing, Chongqing, China,

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Chongqing University Cancer Hospital
    ClinicalTrials.gov Identifier:
    NCT05779111
    Other Study ID Numbers:
    • CQGOG0111
    First Posted:
    Mar 22, 2023
    Last Update Posted:
    Mar 22, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Uterine Cervical Neoplasms

    Study Results

    No Results Posted as of Mar 22, 2023